TC BioPharm (Holdings) 株価情報 (NASDAQ: TCBP)

最新ニュース TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報

TC BioPharm (Holdings)

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings) PLC

Orion Energy Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OESX#NASDAQ">OESX</a>) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. This is a 28.57 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $19.584 million which missed the analyst consensus estimate of $27.266 million by 28.17 percent. This is a 24.59 percent decrease over sales of $25.971 million the same period last year.

Earnings

Earnings Misses

News

OESX

Orion Energy Sys Q3 2025 GAAP EPS $(0.05) Misses $(0.04) Estimate, Sales $19.584M Miss $27.266M Estimate

Needham analyst Charles Shi reiterates Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and maintains $34 price target.

Price Target

Reiteration

Analyst Ratings

AMKR

Needham Reiterates Buy on Amkor Tech, Maintains $34 Price Target

Citigroup analyst Tyler Radke maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Neutral and raises the price target from $39 to $48.

KVYO

Citigroup Maintains Neutral on Klaviyo, Raises Price Target to $48

Citigroup analyst Drew Foster maintains HubSpot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) with a Buy and raises the price target from $750 to $900.

HUBS

Citigroup Maintains Buy on HubSpot, Raises Price Target to $900

The OASIS+ vehicle has an estimated total spend of $60 billion over a maximum of 10 years.

Contracts

ASGN

ASGN Says Its Brand ECS Named As Prime Contractor On $60B OASIS+ IDIQ Contract

THRD

Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times

LASE

Laser Photonics Secures Repeat Order From Bruce Power, Advancing Eco-Friendly Laser Cleaning In Nuclear Plants

Morgan Stanley analyst Dara Mohsenian maintains Edgewell Personal Care (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPC#NYSE">EPC</a>) with a Underweight and lowers the price target from $35 to $32.

Morgan Stanley Maintains Underweight on Edgewell Personal Care, Lowers Price Target to $32

Laser Photonics Receives Order For Second And Third CleanTech 500-CTHD Laser Cleaning System From Sargent & Lundy For Use By Bruce Power In Ontario, Canada

Biotech

Guidance

Health Care

General

RPRX

Royalty Pharma Expects 2025 Portfolio Receipts Of $2.9B-$3.05B, With Operating And Professional Costs Of Approximately 10% Of Portfolio Receipts And Interest Paid Of $260M

Citigroup analyst Ronald Josey maintains Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Neutral and raises the price target from $200 to $217.

EXPE

Citigroup Maintains Neutral on Expedia Group, Raises Price Target to $217

SPGI

S&P Global Authorized Repurchase Of Shares Totaling Up To $4.3B; Expects To Launch An Initial $650M Accelerated Share Repurchase In Coming Weeks

SHOP: -11% &#x7C; <a href="https://www.benzinga.com//node/43619343">Shopify shares are trading lower following Q4 financial results.</a>
&nbsp;
IINN: 33% &#x7C; <a href="https://www.benzinga.com//node/43618385">EXCLUSIVE: Inspira Technologies Tells Benzinga 'Initial ex-vivo testing demonstrates significant bacterial reduction potential for innovative IV dressing technology aimed at preventing bloodstream infections'</a>
&nbsp;
LIPO: 81% &#x7C; <a href="https://www.benzinga.com//node/43617270">Lipella Pharmaceuticals Shares Phase 2a Results For LP-310 In The Treatment Of Oral Lichen Planus, Showing Favorable Safety Profile And Tolerability Of Twice-Daily Oral Rinse</a>

Movers

Trading Ideas

Inspira Technologies Oxy BHN Ltd Ordinary Shares

IINN

LIPO

SHOP

Market-Moving News for February 11th

Needham analyst Quinn Bolton reiterates Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and maintains $70 price target.

LSCC

Needham Reiterates Buy on Lattice Semiconductor, Maintains $70 Price Target

Morgan Stanley analyst Toni Kaplan maintains Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) with a Underweight and lowers the price target from $102 to $100.

BFAM

Morgan Stanley Maintains Underweight on Bright Horizons Family, Lowers Price Target to $100

Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 million by 12.50 percent. This is a 0.34 percent decrease over sales of $596.00 million the same period last year.

Royalty Pharma Q4 2024 Adj EPS $1.16 Beats $1.05 Estimate, Sales $594.00M Miss $678.89M Estimate

S&P Global Sees FY25 Revenue Growth Of 5%-7%, And Adjusted Diluted EPS Of $17.00-$17.25 Vs. $16.92 Estimate

FLXS

GigaCloud Technology Says Purple Innovation, Flexsteel Industries' Brand And Other Furniture Suppliers Has Joined Its GigaCloud Marketplace

Additionally, Anterix has launched a new industry engagement initiative to address and shorten the time to realization of value for Anterix and its customers to allow them to more quickly deploy 900 MHz private wireless broadband networks.&nbsp;

ATEX

Anterix Engages Morgan Stanley To Begin Strategic Review Process After Receiving Inbound Interest In The Company

The recent spotlight on DeepSeek&#8217;s owner, <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">High-Flyer</a> has renewed interest in quantitative hedge funds. These are pooled funds that employ sophisticated mathematical and statistical models to identify and exploit market inefficiencies. Unlike traditional hedge funds that rely on fundamental analysis, quantitative hedge funds focus on statistical patterns and data-driven strategies to generate returns.
<h3 class="wp-block-heading">What Are Hedge Funds?</h3>
Hedge funds, in general, are private investment partnerships that cater to high-net-worth individuals and institutional investors. They are known for their flexible investment strategies and the potential for higher returns which is accompanied by higher risk. Retail investors cannot invest in hedge funds because of the higher amount of risk involved,
Quantitative hedge funds, a subset of this broader category, rely heavily on data analysis and algorithmic trading.
<h3 class="wp-block-heading">Quantitative Hedge Funds: A Deep Dive</h3>
Quantitative hedge funds use complex algorithms to sift through vast amounts of data, including historical price data, economic indicators, and news sentiment, to identify patterns and predict future price movements. These strategies can range from high-frequency trading, where positions are held for fractions of a second, to more long-term, statistically-driven investments.
While the specifics of each fund&#8217;s algorithms are proprietary, several common quantitative strategies exist:
<ul>
<li>Statistical Arbitrage: This strategy exploits temporary price differences between related assets, buying the undervalued asset and selling the overvalued one, profiting from price convergence.</li>
</ul>
<ul>
<li>Pairs Trading: This strategy targets two assets that historically move together, betting on the restoration of their correlation by going long on the underperforming asset and short on the outperforming one.</li>
</ul>
<ul>
<li>Trend Following: This strategy rides established market trends, using algorithms to profit from rising or falling prices.</li>
</ul>
<ul>
<li>Market Neutral: This strategy generates returns regardless of market movements by using algorithms to identify overvalued and undervalued securities, going long on the former and short on the latter, with minimal net market exposure. Leverage is often used to amplify returns and risks.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43614897/auto-slowdown-hits-on-semiconductor-in-q4-q1-outlook-also-dim-ceo-warns-of-persisting-volatility-due-to-the-geopolitical-uncertainty">Auto Slowdown Hits ON Semiconductor In Q4 — Q1 Outlook Also Dim: CEO Warns of &#8216;Persisting Volatility Due To The Geopolitical Uncertainty&#8217;</a>
Why It Matters: Mathematicians, statisticians, and programmers develop and refine their algorithms which are used to employ quantitative strategies. The development of these strategies is heavily reliant on vast amounts of data and sophisticated computing power because processing and analyzing data is crucial for success in this field.
The reliance on algorithms means that unforeseen events or market shocks can trigger rapid and substantial losses. The use of leverage can amplify both gains and losses.
This was evident in the case of High-Flyer too, which lost a third of its investors' money in 2022 amid the volatility in Chinese markets. The fund along with its majority stakeholder &nbsp;Liang Wenfeng <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">apologized</a> to its investors profusely via its official WeChat account after losing their money.
It was after this incident that the company exclusively committed to developing AI technology for the benefit of humanity, forming a new independent research group dedicated to exploring the potential of artificial general intelligence. This restructuring led to the <a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">creation</a> of DeepSeek in 2023.
Price Action: The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively ended higher on Monday. SPY rose 0.68% to $604.85, and QQQ advanced 1.21% to $529.25, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data. In premarket on Tuesday, SPY was down 0.21% and QQQ fell 0.29%.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43521806/deepseeks-hedge-fund-owner-had-multiple-top-projects-before-creating-the-firm-that-fueled-1-trillion-market-cap-erosion-of-ai-stocks">DeepSeek&#8217;s Hedge Fund Owner Had Multiple Top Projects Before Creating The Firm That Fueled $1 Trillion Market Cap Erosion Of AI Stocks</a></li>
</ul>
Photo courtesy: Shutterstock

Market Summary

Markets

Tech

ETFs

As DeepSeek's Owner 'High-Flyer' Comes To Fore, Let's Understand What Is A Quantitative Hedge Fund And How Does It Work

TC BioPharm (TCBP) announced that shareholders have formally approved the recently announced 25% stock dividend. TC BioPharm declared that last wee...

TC Biopharm shareholders approve 25% stock dividend

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC BioPharm conducted a general meeting on December 30, 2024, w...

TC BioPharm Approves Key Resolutions to Enhance Strategic Flexibility

TC BioPharm (TCBP) has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the...

TC Biopharm advances negotiations with acquisition candidates

The latest update is out from TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ). TC Biopharm has announced the approval and distribution of a sp...

TC Biopharm Announces Special Stock Dividend and Temporary Trading Halt

These are the upcoming stock splits for the week of January 6 to January 10, based on&nbsp;TipRanks' Stock Splits Calendar. A&nbsp;stock split&nbsp...

Upcoming Stock Splits This Week (January 6 to January 10) – Stay Invested

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has provided an announcement. TC Biopharm (Holdings) Plc announced that it received a notifica...

TC Biopharm Faces Potential Nasdaq Delisting Due to Bid Price Non-Compliance

TC BioPharm to implement ADS ratio change

19:50 EST TC Biopharm (TCBP) (Holdings) PLC – ADR trading halted, news pending Published first on TheFly – the ultimate source for real-time, marke...

TC Biopharm (Holdings) PLC – ADR trading halted, news pending

TC BioPharm (TCBP) announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has...

TC Biopharm completes initial Cohort B patient dosing in ACHIEVE trial

TC Biopharm (Holdings) Plc Sponsored ADR ( ($TCBP) ) has shared an update. On February 5, 2025, TC BioPharm announced a change in its American Depo...

Comments

TC BioPharm (Holdings)

ニュース

最新ニュース TC BioPharm (Holdings) (NASDAQ:TCBP) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル